Researchers at Stanford have developed a mammalian-cell-based directed evolution platform that combines programmable RNA editing with viral-mediated recombination to enable iterative diversification and optimization of protein and nucleic acid sequences.
Researchers at Stanford University have found that upregulating cathelicidin gene expression can improve the efficacy of a wide variety of treatments as an adjunct therapy.
Researchers at Stanford have developed an IL-7–conjugated lipid nanoparticle (LNP) platform designed to substantially improve mRNA delivery to T cells for direct in vivo T-cell engineering.
Researchers at Stanford have designed, in silico, a series of new human IL-2 mutants that have biased actions on different immune cell subsets, and confer increased signaling potency compared to natural IL-2.
Stanford scientists have discovered novel high molecular weight isoforms of thymic stromal lymphopoietin (TSLP), measured using nanoimmunoassay (NIA), that can serve as a blood-based biomarker for the diagnosis and prognostication of acute graft versus host disease (aGVHD).
Stanford researchers have developed a label-free platform that combines surface-enhanced Raman spectroscopy (SERS) with machine learning to enable rapid, non-destructive profiling of cell identity and functional state at single-cell resolution.
Researchers at Stanford have developed genetically encoded STING agonists that enable controlled activation of the STING pathway from within engineered cells.
Stanford researchers have developed a high-throughput platform to engineer synthetic ETS transcription factors that enhance human T cell function beyond natural TFs, enabling precise and scalable cellular reprogramming for immunotherapy and other therapies.
Stanford researchers have developed a high-throughput platform that designs, delivers, and screens synthetic microRNAs to precisely reprogram human T cells and improve the efficacy of CAR T cell therapies.
Researchers at Stanford have developed constitutively active, programmable synthetic cytokine receptors capable of polarizing human macrophages to a variety of user-defined cell states which may be useful for therapeutic applications.
Hematological cancers like non-Hodgkin's lymphoma have seen a revolution in care due to the advances of targeted cell therapies like CAR-T. However, not all blood cancers have enjoyed the same benefit, hampered by the lack of actionable and specific blood cell targets.
Stanford scientists have discovered a novel method for treating neuroendocrine tumors by engineering T cells with Synthetic Notch (SynNotch) circuits that enable precise and durable tumor targeting while overcoming antigen heterogeneity.
Stanford researchers have suggested ganglioside GM2, which is upregulated with the loss of ganglioside GD2, as a safe alternative target for antibodies and CAR-T cells for cancer immunotherapy.
Stanford researchers have suggested targeting ganglioside GM2, either alone or in combination with ganglioside GD2, to enhance CAR-T therapy for cancer.